Medical cannabis for severe treatment resistant epilepsy in children : a case-series of 10 patients Rayyan Zafar, Anne Schlag, Lawrence Phillips, David J Nutt BMJ Paediatrics Open, 2021, 5, e001234. doi : 10.1136/bmjpo-2021-001234 ABSTRACT Objectives : To report the findings of a case-series of 10 children suffering with intractable epilepsies in the UK to determine the feasibility for using whole-plant cannabis medicines to treat seizures in children. Setting : This study was conducted retrospectively through collecting clinical data from caretakers and clinicians on study outcome variables. Participants were recruited through the MedCann Support and End our Pain charity groups which are patient representative groups that support children [...]
Lire la suiteWhole-plant Cannabis Linked to Large Reduction in Seizures Kelli Whitlock Burton Medscape - Dec 29, 2021. https://www.medscape.com/viewarticle/965756 Whole-plant cannabis is linked to a significant reduction in seizures in children with severe treatment-resistant epilepsy, early research suggests. In a small case series, children with severe treatment-resistant epilepsy treated with a range of whole-plant extract cannabis-based medical products (CBMPs) reported an 86% reduction in monthly seizures. All participants had no improvement with traditional antiepileptic drugs (AEDs). The study adds to a small but growing body of research investigating whole-plant cannabis medicines containing tetrahydrocannabinol (THC) in pediatric epilepsies. Rayyan Raja Zafar "Although we have previously noted the superior efficacy of whole-plant medical cannabis is a previous [...]
Lire la suiteEpidiolex Plus THC May Lower Seizures in Pediatric Epilepsy Randy Dotinga Medscape.com - Oct 14, 2021. https://www.medscape.com/viewarticle/960842 Children and young adults with epilepsy had fewer seizures after combination treatment with the drug Epidiolex, which contains the cannabidiol (CBD), and various doses of tetrahydrocannabinol (THC), the component of cannabis that makes people high in larger quantities, researchers reported. "THC can contribute to seizure control and mitigation some of the side effects of CBD," said study coauthor and Austin, Tex., child neurologist Karen Keough, MD, in an interview. Keough and colleagues presented their findings at the 50th annual meeting of the Child Neurology Society. In a landmark move, the Food and [...]
Lire la suiteLong-Term Efficacy for Epidiolex in Resistant Epilepsy Pauline Anderson Medscape - Dec 17, 2018. https://www.medscape.com/viewarticle/906653 NEW ORLEANS — Results of open-label extension trials show the recently approved drug Epidiolex (GW Pharmaceuticals), a purified formulation of cannabidiol (CBD), is safe and effective beyond a year in patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome, two rare and resistant epilepsy types. "We now have long-term data to say that it still works; the efficacy is not going to drop off, and more importantly, it's still going to be safe and you're not going to learn anything new down the road," study author Anup D. Patel, MD, Section Chief of Pediatric Neurology, [...]
Lire la suiteData Supporting Cannabis for Childhood Epilepsy Remain Scarce Will Pass Medscape.com, September 13, 2021 https://www.medscape.com/viewarticle/958616 Cannabis-based medicinal products (CBMPs) have shown early promise for refractory childhood epilepsy, but positive media attention, as well as pressure from politicians and marijuana advocacy groups, should not supplant clinical trials and acceptable standards of evidence, according to two leading experts. In a recent invited review article, Martin Kirkpatrick, MD, of the University of Dundee (Scotland), and Finbar O'Callaghan, MD, PhD, of University College London suggested that childhood epilepsy may be easy terrain for commercial interests to break ground, and from there, build their presence. "Children with epilepsy are at risk of being [...]
Lire la suiteThe Impact of Cannabidiol on Psychiatric and Medical Conditions Thersilla Oberbarnscheidt, Norman S. Miller Journal of Clinical and Medical Research, 2020, 12, (7), 393-403. Doi : 10.14740/jocmr4159 Abstract Cannabidiol (CBD) is a substance chemically derived from Cannabis sativa and discussed to be non-psychoactive. According to the FDA, marijuana is classified as a schedule I substance; however, hemp which is defined as extracts from marijuana including cannabinoids containing less than 0.3% tetrahydrocannabinol (THC), is excluded from that controlled substance act and available at local convenience stores in the US as it is seen as an herbal supplement. CBD is purported to be used for various medical [...]
Lire la suiteEtats-Unis : l’Epidiolex n’est plus une substance contrôlée Aurélien BERNARD Newsweed.fr, 8 avril 2020 https://www.newsweed.fr/etats-unis-lepidiolex-nest-plus-une-substance-controlee/ GW Pharmaceuticals a annoncé lundi que l’Epidiolex, un médicament à base de cannabidiol (CBD) utilisé dans le traitement de l’épilepsie, avait été retiré de l’annexe V de la Loi américaine sur les substances contrôlées par la Drug Enforcement Administration (DEA). Les personnes qui pourraient en bénéficier pourront dorénavant en obtenir plus facilement. GW a déclaré dans son communiqué qu’il « entamera maintenant le processus de mise en œuvre de ces changements au niveau de l’État et via le réseau de distribution EPIDIOLEX ». Comme pour de nombreux médicaments non-contrôlés, les malades ou leurs [...]
Lire la suiteAbuse potential assessment of cannabidiol (CBD) in recreational polydrug users : A randomized, double-blind, controlled trial Kerri A. Schoedel, Isabella Szeto, Beatrice Setnik, Edward M. Sellers, Naama Levy-Cooperman, Catherine Mills, Tilden Etges, Kenneth Sommerville Epilepsy & Behavior, 2018, 88, 162–171. Doi : 10.1016/j.yebeh.2018.07.027 a b s t r a c t Rationale : Treatment with a highly purified oral solution of cannabidiol (CBD), derived from the plant Cannabis sativa L., demonstrated some evidence of central nervous system (CNS)-related adverse events in patients enrolled in phase 3 trials for treatment of childhood-onset epilepsy. Cannabidiol was categorized as a Schedule 1 substance by the United States Drug [...]
Lire la suiteLe cannabidiol, un agent thérapeutique prometteur ? Benjamin Rolland , Mathieu Chappuy, Patrizia Carrieri SWAPS, 3e et 4e trimestre 2019, n° 92-93, , 5-6. Deuxième cannabinoïde le plus étudié après le THC, sans effet psychoactif, le cannabidiol dispose de propriétés thérapeutiques intéressantes, notamment en psychiatrie. Le point sur les recherches La grande famille des cannabinoïdes Les cannabinoïdes sont un ensemble de substances capables d’activer les récepteurs du même nom (« récepteurs cannabinoïdes »). Il existe deux grandes familles de récepteurs cannabinoïdes, CB1 et CB2. Dans le système nerveux central, c’est surtout CB1 qui est exprimé, alors que CB2 est principalement présent dans le système immunitaire. [...]
Lire la suiteA Systematic Review on the Pharmacokinetics of Cannabidiol in Humans Sophie A. Millar, Nicole L. Stone, Andrew S. Yates and Saoirse E. O’Sullivan Frontiers in Pharmacology, 26 November 2018 https://doi.org/10.3389/fphar.2018.01365 Background : Cannabidiol is being pursued as a therapeutic treatment for multiple conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but literature in humans is not sufficient. The aim of this review was to collate published data in this area. Methods : A systematic search of PubMed and EMBASE (including MEDLINE) was conducted to retrieve all articles reporting pharmacokinetic data of CBD in humans. Results : Of 792 articles retireved, 24 included [...]
Lire la suite